Brooks Laboratories Limited has issued a clarification to BSE Limited regarding recent movement in its share price, responding to an inquiry from the stock exchange dated April 1, 2026. The pharmaceutical company addressed concerns about price volatility under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Regulatory Compliance Statement

The company confirmed it has disclosed all material information with bearing on operations and performance to the stock exchange within stipulated timeframes. Brooks Laboratories emphasized adherence to necessary disclosures in accordance with SEBI Listing Regulations.

Price Movement Clarification

Brooks Laboratories stated it holds no pending unpublished price sensitive information that may influence price or volume behavior in the scrip. The company management declared no awareness of specific reasons behind significant share price changes.

The pharmaceutical firm attributed share price movement and trading volumes to market-driven factors, emphasizing management has no connection with price changes. Company Secretary and Compliance Officer Krutika Rane signed the response, reiterating the organization's commitment to regulatory compliance.

Corporate Governance Commitment

The company assured continued adherence to compliance requirements under Listing Regulations and other applicable laws. Brooks Laboratories maintains its corporate office at The Summit Business Bay, Andheri East, Mumbai, and operates under the oversight of Company Secretary Krutika Rane (Membership No. 66310).

Brooks Laboratories Limited has announced significant developments regarding the composite scheme of arrangement involving its joint venture Brooks Steriscience Limited (BSL). The company provided this update to stock exchanges on March 6, 2026, following earlier communications about the proposed merger scheme.

Regulatory Approval Progress

The Board of Directors of BSL has formally acknowledged the receipt of no-objection and no adverse observation letters from both the National Stock Exchange of India Limited and BSE Limited for the proposed scheme. These regulatory approvals represent a crucial milestone in the merger process.

Scheme Details and Participants

The composite scheme of arrangement and amalgamation involves multiple entities in a complex merger by absorption structure. The scheme was initially approved by BSL's Board of Directors and communicated to stakeholders on September 26, 2025.

The participating entities in this arrangement include:

• Steriscience Specialties Private Limited
• Brooks Steriscience Limited
• Steriscience Pte. Limited
• Strides Pharma Services Private Limited
• OneSource Specialty Pharma Limited

Next Steps and Timeline

BSL's Board of Directors has decided to undertake an additional review process before proceeding with the formal application to the National Company Law Tribunal (NCLT). This strategic pause allows for thorough evaluation while maintaining compliance with regulatory requirements.

The review process will be completed within the six-month approval window granted by the stock exchanges, ensuring the company maximizes the available timeframe for due diligence while preserving the validity of regulatory approvals.

Corporate Governance

The update was formally communicated by Company Secretary and Compliance Officer Krutika Rane, demonstrating the company's commitment to transparent stakeholder communication throughout this significant corporate restructuring process.